Skip to main content
SpringerLink
Log in

Therapie von Hodentumoren

Stadienspezifisch und leitliniengerecht behandeln

  • TOPIC 1 • therapie von hodentumoren
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Der Hodentumor ist in Deutschland der häufigste bösartige Tumor bei jungen Männern im Alter von 20–40 Jahren. Aus bislang ungeklärter Ursache zeigt dieser Tumor in westlichen Ländern eine steigende Inzidenz. Die Zahl der Erkrankungsfälle ist in den letzten 30 Jahren um 50% gestiegen und beträgt heute ca. 11/100 000. Die bei optimaler Therapie erzielbare hohe Kurationsrate von ca. 90% ist nur bei konsequenter Umsetzung der stadienspezifischen und leitliniengerechten Therapieempfehlungen zu erreichen. Der Beitrag gibt einen Überblick zu Diagnose, Therapie und Prognose von Hodentumoren.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14: 3126–3132

    CAS  PubMed  Google Scholar 

  2. Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I. Eur Urol 53: 478–496

    Article  PubMed  Google Scholar 

  3. Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 53: 497–513

    Article  PubMed  Google Scholar 

  4. Warde P, Specht L, Horwich A et al (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance. J Clin Oncol 20: 4448–4452

    Article  PubMed  Google Scholar 

  5. Schairer C, Hisada M, Chen BE et al (2007) Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 99: 1248–1256

    Article  PubMed  Google Scholar 

  6. Van den Belt-Dusebout AW, Wit R de, Gietema JA et al (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370–4378

    Article  PubMed  Google Scholar 

  7. Tandstad T, Dahl O, Cohn-Cedermark G et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27: 2122–2128

    Article  PubMed  Google Scholar 

  8. Albers P, Siener R, Krege S et al (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26: 2966–2972

    Article  CAS  PubMed  Google Scholar 

  9. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: A prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603

    Google Scholar 

  10. Williams SD, Birch R, Einhorn LH et al (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435–1440

    Article  CAS  PubMed  Google Scholar 

  11. Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 16: 702–706

    CAS  PubMed  Google Scholar 

  12. Kondagunta GV, Bacik J, Bajorin D et al (2005) Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23: 9290–9294

    Article  CAS  PubMed  Google Scholar 

  13. Nichols CR, Catalano PJ, Crawford ED et al (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16: 1287–1293

    CAS  PubMed  Google Scholar 

  14. Schmoll HJ, Kollmannsberger C, Metzner B et al (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21: 4083–4091

    Article  CAS  PubMed  Google Scholar 

  15. Motzer RJ, Nichols CJ, Margolin KA et al (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25: 247–256

    Article  CAS  PubMed  Google Scholar 

  16. Collette L, Sylvester RJ, Stenning SP et al (1999) Impact of the treating institution on survival of patients with „poor-prognosis“ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91: 839–846

    Article  CAS  PubMed  Google Scholar 

  17. Beyer J, Kramar A, Mandanas R et al (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 14: 2638–2645

    CAS  PubMed  Google Scholar 

  18. Lorch A, Beyer J, Mollevi C et al (2009) For the International Group on Prognostic Factorsin Relapsed or Refractory Germ-Cell Tumors. Prognostic factors in relapsed or refractory male germ cell tumors: Results from an international study of 1,593 patients. J Clin Oncol 27: 15 s, abstract 5030

    Article  Google Scholar 

  19. Pico JL, Rosti G, Kramar A et al (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16: 1152–1159

    Article  PubMed  Google Scholar 

  20. Kondagunta GV, Bacik J, Donadio A et al (2005) Combination of paclitaxel, ifosfamide and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23: 6549–6555

    Article  CAS  PubMed  Google Scholar 

  21. Bokemeyer C, Oechsle K, Honecker F et al (2008) Combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19: 448–453

    Article  CAS  PubMed  Google Scholar 

  22. Ronnen EA, Kondagunta GV, Bacik J et al (2005) Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 23: 6999–7004

    Article  PubMed  Google Scholar 

  23. Oldenburg J, Alfsen GC, Lien HH et al (2003) Postchemotherapy retroperitoneal surgery remains necessary in in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21:3310–3317

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onkologisches Zentrum, II. Medizinische Klinik und Poliklinik, Onkologie, Hämatologie und Knochenmarkstranplantation mit Sektion Pneumologie, Hubertus Wald Tumorzentrum, Universitäres Cancer Center Hamburg UCCH, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

    F. Honecker & C. Bokemeyer

  2. Klinik für Radioonkologie/MVZ, Universitätsklinikum Tübingen, Tübingen, Germany

    R. Souchon

  3. Urologische Klinik, Krankenhaus Maria-Hilf, Krefeld, Germany

    S. Krege

  4. Onkologisches Zentrum, Hubertus Wald Tumorzentrum, Universitäres CancerCenter Hamburg UCCH, Universitäts-klinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany

    F. Honecker

Authors
  1. F. Honecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Souchon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Honecker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Honecker, F., Souchon, R., Krege, S. et al. Therapie von Hodentumoren. best practice onkologie 5, 4–13 (2010). https://doi.org/10.1007/s11654-009-0201-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-009-0201-9

Search

Navigation